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Research
current practice often involves initiation of
therapy in the acute care setting (hospital),
with long-term management provided in the
community by the general practitioner. For
the patient, this usu lly translates to routine
visits to the pathology service for blood
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Objective:  To identify the views of health professionals, patients and their carers on 
strategies to improve the use and management of warfarin in older patients with atrial 
fibrillation.
Design:  Qualitative study based on analysis of group interviews.
Setting: A major metropolitan teaching hospital, from 1 March to 30 April 2003.
cipants: 14 patients ( 65 years) with established atrial fibrillation and taking 
rin, three carers, 12 specialists, eight general practitioners, six community 
macists, nine hospital pharmacists, and 11 nurses volunteered in response to 
 promoting the study.
lts: Suggested strategies to improve warfarin management targeted support 
ces for GPs and patients. Hospital-based clinicians felt that dissemination of trial 
evidence to GPs to support treatment recommendations is required, and that GPs 
need to enlist allied health professionals in the management of patients taking warfarin. 
GPs preferred access to practical advice from expert colleagues on the day-to-day 
management. Patients requested more information about warfarin therapy, as access 
to information is inadequate, particularly from primary sources (GPs, community 
pharmacists). Verbal and written information are equally important, but a single 
counselling session or supply of a booklet was viewed as inadequate. Participants 
identified various interventions for all levels of warfarin management; from the collective 
input, a framework for management strategies was developed.
Conclusions: Health professionals and patients require more customised information 
MJA 2007; 186: 175–180
to support warfarin use and management.
See also page 197es
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ianD pite evidence to support its use inial fibrillation,1,2 several Austral- studies have shown that warfarin
therapy remains underutilised, particularly
in older patients,3,4 where the day-to-day
management is perceived by clinicians to be
more difficult.5,6 In prescribing warfarin,
tests, regular follow-up by doctors for warfa-
rin dose adjustment, and lifestyle changes
(eg, diet).
Previous research has focused on identify-
ing the barriers to warfarin use and prefer-
ences for treatment options.5,7,8 Widespread
consultation with key prescribers and
patients on how to improve warfarin use
and its day-to-day management is lacking.
Furthermore, to our knowledge, no studies
have explored the broader perspectives of
patients’ carers or other health professionals.
We aimed to explore the attitudes of doc-
tors, other health professionals, patients and
carers, to identify ways to improve the man-
agement of warfarin in older patients.
METHODS
A series of group interviews, involving
health professionals, patients and carers,
was conducted at Royal North Shore Hospi-
tal, Sydney between 1 March and 30 April
2003. Each interview involved an independ-
ent facilitator experienced in conducting
focus groups and unknown to the partici-
pants, a co-facilitator, and a scribe. Discus-
sion was facilitated using a brief topic guide,
listing open-ended questions such as:
• What has been your experience with
warfarin therapy?
• How do you feel about taking/managing
warfarin?
• How could warfarin use be improved?
Participants
Participants were recruited using a hybrid of
criterion-based sampling (ie, selecting peo-
ple involved with warfarin), with maximum
variation,9 providing externally homoge-
nous (eg, comprising patients, hospital clini-
cians, GPs, nurses or pharmacists) but
internally heterogeneous (ie, differing in sex,
culture and experience) groups.10
Patients were recruited by voluntary
response to flyers within the hospital and
the local community (aged care centres,
hostels and retirement facilities). For
recruiting health professionals, flyers were
distributed to relevant hospital departments
through the mail system and at case confer-
ences, clinical seminars and journal clubs.
Flyers were emailed or faxed to GPs listed
with the Northern Sydney Division of Gen-
eral Practice, and to community-based
nurses and pharmacists listed on an aged
care services directory.
All participants were offered a nominal
payment of $25.00 plus reimbursement of
travel expenses, and refreshments, once they
gave informed written consent. Northern
Sydney Health Ethics Committee approved
the study.
Data analysis
The audiotaped discussions were tran-
scribed verbatim then thematically analysed,
using a phenomenological approach,10,11 by
inductively coding significant statements
within the transcripts into themes, followed
by re-review of the data for verification.12
Validity was attained by investigator triangu-
lation and respondent validation; the co-
facilitator and scribe independently ana-
lysed the transcripts before reaching a con-
sensus,13,14 then compared this against the
scribe’s supplementary notes. Finally, after
review by the main facilitator, the findings
were fed back to volunteer participants from
each group to ensure the accuracy of the
interpretation.14
RESULTS
From eight group interviews (n = 63, Box 1),
four core themes arose: day-to-day experi-
ences with warfarin therapy; dependence on
the GP in warfarin therapy; barriers to war-
farin use; and strategies to improve warfarin
use. The last theme is the subject of this
article, and comprised four sub-themes:
• need for information to support warfarin
use;JA • Volume 186 Number 4 • 19 February 2007 175
RESEARCH• deficiencies in the provision of informa-
tion to patients;
• access to dedicated services in the com-
munity setting; and
• delegation of responsibility for warfarin
therapy.
Need for information to support 
warfarin use
Across all of the groups, an overarching
theme was the perceived paucity of informa-
tion to support warfarin therapy across the
continuum of care.
Information for decision making
GPs and hospital-based doctors felt that
there is insufficient information to support
the decision to initiate warfarin therapy. GPs
were perplexed about the decisions made in
hospital to begin warfarin therapy, and
wanted a wider dissemination of clinical
trial evidence to provide a rationale. They
requested that specialists be more proactive
in offering this information, similar to the
way that industry representatives promote
their products.
I thought that [warfarin] was just a bit
better than aspirin, or [clopidogrel] . . .
We see drug reps each week telling us
about how much more wonderful one
[drug is] on top of the other. But who
has ever seen a drug rep pushing warfa-
rin? [GP]
Patients likewise needed more informa-
tion on the role and relative importance of
warfarin therapy, as this affects their deci-
sion to accept, and hence continue with,
warfarin.
I need motivation. I need to know
that . . . it is worthwhile doing, because
if I’ve got any doubts I might stop it
entirely. [Patient]
Health professionals, particularly nurses,
collectively expressed a need to document
and communicate information on the deci-
sions to initiate warfarin therapy, expressing
uncertainty as to whether patients’ cogni-
tive, functional and social status are consid-
ered in these decisions. Geriatricians
focused on the risks of therapy, asking pre-
scribers to justify their decisions, and cardi-
ologists felt that GPs particularly need to
engage in this process, recommending spe-
cific “prompts” (decision aids) to help assess
and document a patient’s suitability for war-
farin therapy. Hospital pharmacists sug-
gested explicit, objective and practical
measures to routinely obtain patient-specific
information for decision making, as a risk-
reduction strategy.
We did a [mini mental state examina-
tion] on everyone . . . [I] raised the goal-
post to make it that [patients scoring]
above 22 out of 30 could self-medicate
and were cognitively good enough to be
able to do it. [Hospital pharmacist]
Information for ongoing management
To support ongoing management in the
community, there was widespread need for
more information, particularly among GPs,
who wanted practical and interactive advice,
rather than position statements, for dealing
with acute situations (eg, high international
normalised ratios [INRs], bleeds).
Everybody is different . . . a 40 kg 90-
year-old lady is going to be different to a
30-year-old fat guy . . . you can’t have
exactly the same for everyone, but I
have never heard a haematologist talk
about how warfarinisation should be
done. [GP]
A warfarin update session would be
really useful . . . because we are out
there . . . day to day . . . prescribing it
and testing it. [GP]
Cardiologists and hospital pharmacists
supported this, but varied in their
approaches. Cardiologists focused on practi-
cal, simply formatted, written information
for managing day-to-day situations, as con-
tinuing education seminars were of limited
benefit, whereas pharmacists felt that writ-
ten methods would be ineffective.
[An] educational device for the GPs . . . a
card that you either stick on the wall or
put in your top drawer . . . a quick
glance . . . how to start them off on
warfarin, do the INRs, when to make an
adjustment. [Cardiologist]
Perhaps an article [in a medical journal]
as GPs have to do obligatory [continu-
ing medical education] but quite often
you reach the doctors who are pretty
1 Characteristics of the participants in the eight focus groups
Number (Group composition)
Mean age in 
years ±SD (range)
Mean years with 
warfarin* ±SD (range)
Patients and carers I
7 (6 patients, 1 carer; 3 M, 4 F) 78.9 ±4.1 (72–83) 11.0 ± 12.4 (1–29)
Patients and carers II
10 (8 patients, 2 carers; 5 M, 5 F) 76.0 ± 9.2 (65–91) 3.1 ± 4.6 (0.5–15)
Clinicians I: aged care
6 (5 consultants, 1 registrar; 2 M, 4 F) 42.0 ± 10.7 (32–57) 10.75 ± 10.1 (3–26)
Clinicians II: cardiology/general medicine
6 (3 consultants, 3 registrars; 4 M, 2 F) 41.0 ± 13.8 (28–57) 12.0 ± 10.7 (2–25)
General practitioners
8 (3 from small practices of  2 GPs, 5 from large 
practices of > 2 GPs/medical centre; 6 M, 2 F)
51.8 ± 11.1 (42–75) 20.9 ± 12.9 (10–49)
Aged care nurses
11 (3 aged care ward nurses, 2 aged care clinical 
nurse specialists/consultants, 4 home-nursing 
service or assessment nurse, 1 hospital-to-
community liaison nurse, 1 hospital-to-community 
liaison pharmacist; 0 M, 11 F)
42.5 ± 10.4 (25–54) 18.9 ± 11.1 (3.5–33)
Hospital pharmacists
9 (4 specialist pharmacists [cardiology, aged care, 
neurology], 4 rotational/ward pharmacists, 
1 outpatient pharmacist; 1 M, 8 F)
39.6 ± 11.8 (26–56) 17.9 ± 13.2 (3–36)
Community pharmacists
6 (5 senior community pharmacists, 
1 graduate pharmacist; 5 M, 1 F)
50.5 ± 16.9 (23–67) 24.9 ± 17.3 (0.5–40)
* Years with warfarin means number of years practising in specialty, or number of years taking warfarin, 
or number of years caring for a warfarin user, for health care professionals, patients, and carers, respectively. 
M = male. F = female. Each group interview lasted an average of 1 hour (range, 45–80 minutes). ◆176 MJA • Volume 186 Number 4 • 19 February 2007
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macist]
Among all of the health professionals,
community pharmacists felt that they have
least opportunity to assist patients and GPs,
as they often lack access to both specific
information on the patient’s warfarin regi-
men and appropriate resources, and are
unable to track blood test results because
they are not linked into the reporting system
between the patient, pathologist and GP.
You make an effort to keep a record . . .
of what they are taking . . . [and] ask
them each time, but if you print it on
the bottle it is likely to change [to a]
different dose altogether. It could
change three times. [Community phar-
macist]
Hospital-based pharmacists acknow-
ledged this problem, and suggested that
community pharmacists could make better
use of their computer software to help man-
age patients.
Deficiencies in the provision of 
information to patients
The participants universally agreed that the
provision of information to patients is inad-
equate, including poor use of existing
resources. The supply of the standard “little
blue warfarin booklet” (manufacturer-pro-
duced) is insufficient as a stand-alone meas-
ure, as patients need to practically engage
with its contents to achieve adherence.
Patients and carers felt that verbal and writ-
ten information are equally important, but
need to be provided in a paced manner with
an opportunity to verify the patient’s under-
standing at a later time.
Yesterday . . . another young person got
a [deep vein thrombosis] and was put
on warfarin . . . she went [to the commu-
nity pharmacy] with her prescription,
waiting for the pharmacist to counsel
her and got absolutely zip counselling.
So after she got the tablets she asked,
“Oh, actually, have you got a book? I
would like a book”. “Oh no, no, I don’t
think so.” She was shocked. [Hospital
pharmacist]
Better use of the books . . . if they had
the current dose written and they
brought that with them . . . it could be
checked by the pharmacist and GP.
[Community pharmacist]
I would personally prefer that I read the
book first and then come back and say
“I am not sure about this or that; could
you explain this to me?” [Patient]
The cardiologist . . . says you should cut
out certain food, vegetables, or reduce
the quantities . . . I found it very difficult
to sit on the other side of his desk and
try and make notes of what he was
saying. Now to him it is a regular thing,
it is a routine thing . . . for me it is the
first time I hear this. For 50 years I have
been eating this or that . . . I don’t think
it should be left verbally . . . [You]
should be given a briefing sheet or
something to take away . . . [then] see
your GP and he follows this up with
verbal advice. [Patient]
Need for tailored information
Both health professionals and patients felt
that existing written information is subopti-
mal in content, with regard to the day-to-
day warfarin management issues that appear
to cause most problems, including drug
interactions, complementary medicines, and
dietary vitamin K intake. A suggested strat-
egy for conveying this information was
“take-home” information tailored for older
patients.
An anticoagulant card . . . lists all the
interacting medications and things like
that . . . a list of things they could take
and couldn’t take and what they
couldn’t eat, and it’s in big writing in a
bigger book and easier to read. [Cardiol-
ogist]
Patients wanted detailed information to
increase their confidence in the therapy,
including better explanations of the reasons
for taking warfarin, how it works, how dose
adjustments are made, and observed phe-
nomena (eg, bruising, variable INR results).
They expressed dissatisfaction with the lack
of precautionary information about drug
interactions, as verbal advice was sometimes
retrospective.
I certainly get interactions with different
things, but I haven’t been told . . . [I
took] antibiotics for this bad flu that I
had . . . no, no I hadn’t [been warned
beforehand] and I was a bit surprised,
but once you get the bad [INR] reading
then [the doctor] says, “Oh yeah that
was caused by such and such”. But you
already knew that. [Patient]
Alternative modes of education
A need to provide broader information
about warfarin, to raise its profile and dispel
some of the myths, via other modalities and
enlisting other allied health carers, was
highlighted. Hospital pharmacists favoured
a television campaign, given its effectiveness
in other areas of medicine and the opportu-
nities to use an array of health and medi-
cine-based television programs (eg, All
Saints, Good Medicine).
Education is the way to go, really. Per-
haps if we put it in bigger terms . . . a
short documentary . . . so that they are
not so fearful as soon as you mention
warfarin. [Hospital pharmacist]
A nurse is capable of educating a
patient, but what about pathology col-
lectors? [Hospital pharmacist]
Access to dedicated services in 
the community setting
Patient surveillance
Community-based surveillance and support
of older patients was proposed by hospital
pharmacists and nurses, who recognised
that education alone would not guarantee
risk-free warfarin use. Mobile community-
based services were recommended, as hos-
pital-based anticoagulant clinics were con-
sidered of limited assistance to the at-risk
older population. GPs suggested specialised
community liaison services, including home
visits, using qualified pharmacists to
improve the surveillance of patients, but
were opposed to a greater role for the gen-
eral community pharmacist, as they were
perceived to be underqualified to provide
higher level cognitive services (eg, patient
education, counselling, and therapeutic
drug monitoring).
In the elderly, you are still going to have
a proportion who, regardless of educa-
tion and good GPs, because of what
they have to do themselves, are not
going to be capable . . . you could edu-
cate them until you are blue in the face
and they still wouldn’t be able to see the
difference between a purple and a green
tablet. If warfarin is the best thing for
that selected few, then perhaps they
need community help for administra-
tion. [Hospital pharmacist]
If they are in there looking at the patient
in-house . . . then that is probably quite
useful . . . I usually don’t have the time
. . . If the pharmacist is actually sitting
down with them and looking at how
they are managing their tablets at home
. . . [monitoring] compliance [and] sug-
gesting that the dosette is the way to goMJA • Volume 186 Number 4 • 19 February 2007 177
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way actually. [GP]
Access to information and resources
There was general agreement that access to
information and resources within the com-
munity setting needs improvement, as edu-
cation in the hospital setting was perceived
as ineffective. Even patients who received
comprehensive education in hospital stated
that they found it difficult to apply the
knowledge once discharged, as there is no
ongoing reinforcement. Face-to-face accessi-
ble support and advisory services in the
community setting are necessary, but
patients did not feel that GPs alone could
offer this.
I was in hospital and the pharmacist
came and read the book to me in the
hospital. She spent a long time making
me understand . . . I just accepted it. . .
lots of information, as much as I
needed, but when I got home and prac-
tised, I found [the INR] was up, every
time I rang the doctor, every 2 weeks I
would give blood and it would alter. I
just wondered, what is the good of it?
[Patient]
I go to an endocrinologist. There is a
diabetes educator attached to the
practice . . . who fills me in and gives me
all the reasoning and good motivation to
keep at it . . . I wouldn’t mind there
being . . . a warfarin blood-thinning edu-
cator around the traps that you could
phone or go to. [Patient]
Although community pharmacists are
ideally placed and trained to contribute to
ongoing patient education, hospital phar-
macists were disappointed that their com-
munity peers contributed minimally to
warfarin education, but GPs were worried
about increasing their involvement. Patients
reported variable experiences at community
pharmacies, and were most satisfied when
information was provided in a caring atmo-
sphere.
It’s not like they can’t educate them, but
I don’t think they are aware that there
are people out there that don’t know
anything about their warfarin. [Hospital
pharmacist]
If they are going to be explaining warfa-
rin again, I would want that to be my
role because I have got the responsibil-
ity if it goes wrong. [GP]
It may create conflict with the patient
too . . . especially if the other health
professional said something [different].
[GP]
We go to [a pharmacy] just up on the
corner . . . they know warfarin and they
always check up to see that the thing
that has been prescribed is right for me
to take . . . a very good pharmacist . . .
Sometimes if I get a prescription from
the doctor . . . she will say, I had better
ring the doctor about this. [Patient]
Although community pharmacists agreed
that they could be more involved in warfarin
counselling, both initially and on follow-up,
surveillance of patients was perceived as the
role of nurses and GPs.
Delegation of responsibility for 
warfarin therapy
Participants assigned responsibility for man-
aging warfarin therapy to the GP and the
patient, with emphasis placed on the need
for patients to assume ownership of their
therapy, both in acknowledging the risks
and facilitating its management, and not
simply relying on the GP. However, patients
felt that they already assume this role, in the
absence of other support, as neither the GP
nor the community pharmacist is well
resourced.
“Is this new tablet alright with my war-
farin?” is a valuable question that they
should always ask. [Nurse]
Patients have wonderful trust in their
GPs, which we don’t want to interfere
with, but they do seem to think that the
GP is going to remember and know
every detail. [Hospital pharmacist]
The local doctor is great for prescribing
the next amount to take according to
the INR . . . but I just feel that I am a bit
alone, it is a bit of a journey travelling
solo. [Patient]
The doctor looked [the interaction with
warfarin] up on the computer and said,
“deadly, don’t take any more” . . . and yet
I had asked the pharmacist . . . because
[with] any new drug you like to know
what it is, and she said “well there is
nothing on our computer . . . just watch
for any black spots on you” . . . I have
got to go back from him and feed her
the information that she wasn’t aware
of. [Patient]
Synopsis of strategies
The strategies expressed by the participants
to improve warfarin use were categorised
and summarised along a continuum of pro-
cesses in the use of this therapy (Box 2).
DISCUSSION
To our knowledge, this is the first study to
have concurrently examined the perspec-
tives of clinicians, allied health professionals
and patients regarding appropriate strategies
to improve warfarin use and management in
Australia. Although studies have previously
explored prescriber and patient preferences
for selecting treatment options,5,7,8 or have
identified interspecialty differences in pre-
scribing,5,15,16 none have concurrently
gauged opinions on how to enhance thera-
peutic management.
Several important issues emerged from
our study. First, despite a relative paucity of
evidence about the risk versus benefit of
warfarin therapy in older patients, there is
room for improvement in decision-making
processes, particularly in the documentation
and communication of decisions. Before ini-
tiation of therapy, risk assessments need to
be performed and documented more care-
fully, as there is uncertainty as to how
rigorously clinicians consider various fac-
tors. Interventions involving comprehensive
assessment, with systematic documentation
and communication, can assist in selection
of appropriate antithrombotic therapy for
individual patients,17 and may help clarify
the perceived underutilisation of warfarin in
older patients.
It was widely acknowledged that GPs
need practical information on how to apply
evidence from clinical trials to individual
patients. However, while GPs preferred face-
to-face contact with clinicians to discuss
issues and ask questions, hospital-based cli-
nicians and allied health professionals pre-
ferred paper-based resources. The value of
live contact is highlighted by an Australian
study reporting an improvement in GPs’
knowledge and confidence in prescribing
warfarin following face-to-face academic-
detailing visits.18 Although a multitude of
guidelines have been developed, ranging
from small practice-based protocols to con-
sensus statements,19 their utility is depend-
ent on the evidence and the process by
which they are developed,20 and is limited
by clinicians’ beliefs that guidelines are inap-
plicable to their patients.21-23
Previous studies examining patient prefer-
ences for using warfarin versus other thera-
pies have not sought to identify patients’
needs for resources to support the therapy.7
Patients in our study felt somewhat aban-
doned in their management of warfarin, and
felt that they have no option other than to
undertake independent research because of
the limited accessibility of the GP, lack of178 MJA • Volume 186 Number 4 • 19 February 2007
RESEARCHinformation from community pharmacists,
and non-availability of services for ongoing
support, advice, and education. These find-
ings are concerning, given that patient
knowledge regarding warfarin is generally
poor,24,25 and this influences anticoagula-
tion control.24 Yet our findings suggest there
is limited effort toward rectifying this prob-
lem, perhaps reflecting an assumption by
health professionals that other colleagues are
educating patients. Our findings highlight
that additional counselling at every oppor-
tunity, from all involved, is warranted and
must cater to individual patient needs rather
than relying on suboptimally formatted
mass-produced written information.26,27
Internationally, support services to moni-
tor and educate patients on warfarin therapy
are coordinated by allied health profession-
als,28,29 and in our study, participants, par-
ticularly cardiologists, felt that GPs could
make greater use of allied health services
(eg, pharmacists and nurses) in the commu-
nity. However, community pharmacists did
not see a need for their own greater involve-
ment, and GPs perceived such services to be
of limited value, preferring practical advice
from consultants. The responses of both GPs
and pharmacists highlight an important
issue: the entire, significant responsibility
for the management of warfarin therapy has
been defaulted to the GP. Allied health pro-
fessionals must recognise their contributions
to and responsibilities in warfarin therapy, as
this itself may be a major step forward in
improving its management in the commu-
nity setting.
Study limitations
In conducting group interviews, bias may be
introduced though the facilitation of the
discussions, dominance of individuals, and
in the interpretation of the results. However,
the main facilitator and the study investiga-
tors functioned independently, were not
involved in a dependency relationship with
any of the participants, and necessarily set
aside all prejudgements about the topic in
data analysis.12 Because recruitment was
voluntary, the sample may have been biased
toward those wanting to express a particular
viewpoint, especially grievances, and may
not be generalisable to most key players in
warfarin management. However, the sample
represents a diversity of experiences and
perspectives on this issue.
Resource limitations precluded a larger
sample size, and although each discussion
was facilitated until no new issues emerged,
we were unable to hold multiple sessions to
ensure theme saturation,12 nor ascertain
additional views (eg, junior medical offic-
ers). Because of the small number of carers,
it was not fully elucidated whether their
perspectives differ from those of patients;
however, the perspectives of both patient
and carer groups, as a whole, were similar.
Because the analysis involved anonymised
transcripts, we were unable to correlate per-
spectives with participants’ age, sex, loca-
tion, or therapeutic regimen.
Our study suggests that very simple meas-
ures, such as disseminating information to
patients and GPs, and the participation of
allied health professionals, may have some
far-reaching effects in terms of improving
the use and management of warfarin. Much
more intervention by all health professionals
is required, and further research should
explore the development, implementation
and evaluation of new resources and strate-
gies, given the opportunities to adopt newer
technologies.
2 Potential strategies at different levels of intervention to improve long-term 
warfarin use and management
Hospital-based decision-making processes for the prescribing of warfarin by clinicians
• Further clinical research to quantify the risks of warfarin in the elderly population and to 
identify the strict pathophysiology of stroke in the presence of atrial fibrillation
• Feedback from general practitioners about post-discharge outcomes
• Systems for the complete and official assessment of patients (eg, clinical pathways, consent 
forms, development of a National Warfarin Register)
Community-based decision-making processes for the prescribing of warfarin by GPs
• Wider dissemination of pertinent trial evidence to GPs, to support and promote warfarin 
use in this setting
• Practical consensus guidelines from clinicians to assist GPs in treatment initiation, dosage 
adjustment, and in the handling of difficult or adverse situations
• Refresher courses about basic warfarin pharmacology
• Explicit instructions to GPs on discharge
Long-term patient monitoring in the community setting
• Greater use of external pathology services with systems for patient follow-up for routine 
INR testing
• Anticoagulant clinics for centralised patient care
• Virtual anticoagulant clinics (ie, INR results, GP messages to individual patients, generic 
warfarin advice) that could be accessed by patients and coordinated by GPs with allied 
health professionals
Patient surveillance (pharmacovigilance) in the community setting
• Outreach/hospital-to-community liaison facilities to assist GPs, using allied health 
professionals for ongoing patient assistance with dose administration, monitoring, and 
pharmacovigilance
• Carer involvement (family, home-nursing services)
• Vigilance and referral by pathology services
• Devices for identifying patients (cards, bracelets)
Patient and carer education and information services
• Coordinated inpatient education, for patient and carers, with appropriate measures for 
verifying the patient’s understanding of warfarin
• Development of appropriate counselling and educational tools for the elderly and wider 
community (eg, larger type for printed materials, videos, audiocassettes, television)
• Community pharmacist intervention and patient counselling
Ongoing support services for patients and carers on a long-term basis
• Readily accessible information and support services on a long-term basis, to assist patients 
with queries and provide consistent practical advice regarding warfarin use (eg, dietary 
restrictions, management of bleeds, problem avoidance)
• Patient forums to provide opportunities for voicing experiences and concerns objectively 
with peers
INR = international normalised ratio. ◆MJA • Volume 186 Number 4 • 19 February 2007 179
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